Westlake Village biotech company MannKind restructures debt
MannKind announced Oct. 23 that it had restructured debt due in 2018, exchanging $27.7 million in convertible notes for $23.7 million due in October of 2021 and nearly 1 million shares of its common stock. The new convertible senior subordinated exchange notes have a rate of 5.75 percent, the Westlake Village-based biotech company said in Read More →
Cal Poly SLO, Amazon team up on digital transformation
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Ventura County has need for faster broadband speed
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Cal Poly SLO startups will have access to capital
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Semtech partners with Chinese bike-sharing company
Camarillo Internet of Things company Semtech struck up a partnership with Chinese bike-sharing company ofo, using its long-range, low power wireless technology to keep tabs on ofo bikes. Called LoRa, the network technology enables ofo to track bikes in remote or densely constructed areas. The company provides bike-sharing in more than 180 cities worldwide, using Read More →
Amgen studying genes to target pain conditions
For the next year, Amgen and Boston Children’s Hospital will use genetic analysis to study pain sensitivity. The biotech giant based in Thousand Oaks will work with patients who have abnormal pain conditions, and the hospital will validate genetic markers as potential targets for new therapies, the two announced in a press release on Oct. 16. “Traditional Read More →
Amgen settles with AbbVie over Humira biosimilar litigation
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.